Vaccination was also associated with an 25% lower risk of stillbirth and an 9% lower risk of neonatal intensive care admission, as well as a 17% lower risk of congenital anomalies, according to the study abstract. The findings showed that Hormone therapy significantly relieved moderate or severe vasomotor symptoms (VMS) in women enrolled at baseline. All participants were followed for ten years to track changes in cardiovascular risk factors and the occurrence of major adverse events. “Gout itself appears to confer an additional burden of cardiovascular risk that persists even after accounting for baseline health and decade-long changes,” they noted. Ref: Ghang, B., Kim, J., Kang, T., & Kim, H. J. Ten-year cardiovascular risk changes and major adverse events in gout patients.